ClinicalTrials.gg
RecruitingNCT06399510Updated May 3, 2024

Electrolyte Balance Effects of Sterofundin Versus Normal Saline in Diabetic Ketoacidosis

An interventional study of Sterofundin fluid therapy in Treatment Diabetic Ketoacidosis, Electrolyte Balance Effects, sponsored by Universiti Sains Malaysia. Recruiting at 1 site in Malaysia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Universiti Sains Malaysia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this prospective single centered randomized control trial is to compare the electrolyte balance effects between Sterofundin and Normal Saline in Diabetic Ketoacidosis patients. The main questions it aims to answer are:

i. Is there any difference in duration of bicarbonate (HCO3-) to reach equal or more than 15mmol/L from the initial blood taking in between Sterofundin and NS fluid use in DKA patients? ii. Is there any difference in the level of post-infusion serum sodium (Na+) between Sterofundin and NS fluid use in DKA patients? iii. Is there any difference in the level of post-infusion serum potassium (K+) between Sterofundin and NS fluid use in DKA patients?

Patients will be randomized in a 1:1 ratio to receive IV Sterofundin (intervention) or IV Normal Saline (standard care). The patient will have the respective fluid regime as the main fluid therapy during the first 24 hours of ICU stay. If patients were randomized to the control arm, the fluid regime for the first 24 hours in ICU will be normal saline. If patients were randomized to the interventional arm, the main fluid therapy during the first 24 hours of ICU stay will be Sterofundin.

02

Conditions studied

  • Treatment Diabetic Ketoacidosis, Electrolyte Balance Effects

Browse trials for

03

In context

Diabetic Ketoacidosis

76 studies on the registry are indexed under Diabetic Ketoacidosis; 17 are open to participants now.

This study's planned enrollment of 58 is below the median of 66 across 44 interventional studies indexed under Diabetic Ketoacidosis.

Browse Diabetic Ketoacidosis studies →

Lead sponsor

Universiti Sains Malaysia is the lead sponsor of 177 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • DKA.
  • Aged ≥ 18 years old.
  • Patients admitted to ICU \< 12 hours after initial fluid resuscitation from emergency department/ ward.

Exclusion criteria

Exclusion Criteria:

  • End stage renal failure
  • Heart failure
  • Started treatment of sodium bicarbonate infusion prior to ICU admission
  • Known allergy to Sterofundin
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Active comparator
    Normal Saline

    If patients were randomized to the control arm, the fluid regime for the first 24 hours in ICU will be normal saline.

    Other: Sterofundin fluid therapy

  • Experimental
    Sterofundin

    If patients were randomized to the interventional arm, the main fluid therapy during the first 24 hours of ICU stay will be Sterofundin.

    Other: Sterofundin fluid therapy

Interventions

  • OtherSterofundin fluid therapy

    Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.

06

What researchers measure

Primary outcomes

  1. The duration taken for serum HCO3 ≥ 15 within 24 hours ICU admission.

    Time frame: 24 Hours

  2. Mean difference of serum sodium level between Sterofundin and normal saline fluid use in diabetic ketoacidosis patients

    Time frame: 24 Hours

  3. Mean difference of serum potassium level between Sterofundin and normal saline fluid use in diabetic ketoacidosis patients.

    Time frame: 24 Hours

Secondary outcomes

  1. The Need of Renal Replacement Therapy

    Time frame: 30 days

  2. Mechanical ventilation day

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Hospital Universiti Sains Malaysia
    Kubang Kerian, Kelantan 16150, Malaysia
    Recruiting
    • MOHD ZULFAKAR BIN MAZLAN, Master · Contactzulfakar@usm.my · +6097673000
    • JIE SHI HOW, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

Of 16 interventional studies with no phase under Diabetic Ketoacidosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 3, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Mar 31, 2025
CompletionEst.
Apr 30, 2025
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06399510
Responsible party
Mohd Zulfakar Mazlan, MBBS (Associate Professor, Universiti Sains Malaysia) — Principal investigator
First posted
May 3, 2024
Start date
Mar 1, 2024
Primary completion
Mar 31, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
May 3, 2024

Study contacts

Shi Jie How
Contact
shijie.how@gmail.com
+601151362495

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion